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Fibroproliferative diseases, including pulmonary 
fibrosis, liver cirrhosis, and cardiovascular and 
renal fibrosis, are caused by chronic inflamma-
tion subsequent to persistent tissue damage 
(Wynn, 2007). Unlike liver cirrhosis, which, in 
many developing countries frequently follows 
chronic infection with hepatitis B or C virus, 
pulmonary fibrosis, and particularly idiopathic 
pulmonary fibrosis (IPF)—the most frequent 
and devastating form of the disease—typically 
follows  noninfectious  (i.e.,  physicochemical) 
tissue injury (Rogliani et al., 2008).
Epithelial cells have recently been shown to 
play critical roles in the initiation and perpetu-
ation of inflammation and fibrosis (Hardie et al., 
2009). Specifically, altered repair triggered by 
epithelial injury has been suggested to contrib-
ute to the pathogenesis of IPF (Rogliani et al., 
2008). Thus, the roles of pulmonary epithelial 
cells in the inflammatory cascades activated 
after noninfectious injury, and the key signal-
ing mediators of this process, are now being ac-
tively investigated.
The Th17 response was originally described 
as providing protective immunity against pul-
monary infection (Aujla et al., 2007; Korn et al., 
2009). The recent identification of TGF- and 
IL-6/IL-1 as cytokines that promote Th17 dif-
ferentiation, IL-23 as a signal for Th17 cell sur-
vival and effector function, and RORt and 
ROR as Th17 lineage-specific transcription 
factors (Weaver et al., 2007; McGeachy and Cua, 
2008; Korn et al., 2009) confirmed the identity 
of Th17 cells as a distinct inflammatory T helper 
cell subset. Th17 cells participate in the initial 
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Pulmonary fibrosis is a potentially life-threatening disease that may be caused by overt or 
asymptomatic inflammatory responses. However, the precise mechanisms by which tissue 
injury is translated into inflammation and consequent fibrosis remain to be established. 
Here, we show that in a lung injury model, bleomycin induced the secretion of IL-6 by 
epithelial cells in a transglutaminase 2 (TG2)–dependent manner. This response represents  
a key step in the differentiation of IL-17–producing T cells and subsequent inflammatory 
amplification in the lung. The essential role of epithelial cells, but not inflammatory cells, 
TG2 was confirmed in bone marrow chimeras; chimeras made in TG2-deficient recipients 
showed reduced inflammation and fibrosis, compared with those in wild-type mice, regard-
less of the bone marrow cell phenotype. Epithelial TG2 thus appears to be a critical inducer 
of inflammation after noninfectious pulmonary injury. We further demonstrated that 
fibroblast-derived TG2, acting downstream of transforming growth factor-, is also impor-
tant in the effector phase of fibrogenesis. Therefore, TG2 represents an interesting poten-
tial target for therapeutic intervention.
© 2011 Oh et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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of IB (Park et al., 2006), it may link tissue injury and inflam-
matory responses. Recently, we showed that activation of TG2 
in epithelial cancer cells induces IL-6 production, resulting 
in enhanced tumor progression (unpublished data). Because 
TG2 has also been implicated in TGF- activation (Kojima   
et al., 1993), it may activate both TGF- and inflammatory 
signals (including those induced by IL-6), leading to Th17 
differentiation. Moreover, dysregulated activation of TG2 has 
been observed in various human inflammatory diseases, in-
cluding newly defined Th17-mediated diseases (Kim, 2006). 
On this basis, we suggest that TG2, in conjunction with Th17 
cells, may provide the fundamental link between tissue injury 
and inflammation.
In this study, we used bleomycin (BLM)-induced pulmo-
nary fibrosis as an experimental model of human IPF. Using 
bone marrow chimeric mice generated from WT and TG2-
null mice, we demonstrate two important points: first, that 
epithelial cells are critical in the initiation and perpetuation of 
the inflammation that leads to fibrosis, and second, that epithe-
lial TG2 activity after noninfectious injury is essential for in-
ducing IL-6 production, which, in turn, triggers Th17-mediated 
inflammatory cascades that are activated after acute lung dam-
age and that lead to permanent tissue damage in asthma and 
chronic obstructive pulmonary disease (Traves and Donnelly, 
2008). It further appears that the Th17 response may play an 
important role in the amplification of the inflammatory re-
sponse after noninfectious pulmonary injury (Lo Re et al., 
2010; Sonnenberg et al., 2010; Wilson et al., 2010). However, 
the factors that induce Th17 responses after noninfectious 
tissue damage in vivo remain to be identified.
Transglutaminase 2 (TG2) is a calcium-dependent enzyme 
that catalyzes the cross-linking of proteins (Lorand and Graham, 
2003). Irreversible cross-linking of extracellular matrix (ECM) 
proteins by secreted transglutaminase is important in promot-
ing the net accumulation of ECM molecules (Verderio et al., 
2004). Elsewhere, the essential role of TG2 in hepatic and re-
nal fibrosis during the effector phase of fibrogenesis has been 
confirmed (Shweke et al., 2008; Elli et al., 2009).
A potential role for TG2 in inflammation has also recently 
been  highlighted. As TG2  is  induced  by  various  physical, 
chemical, and biological stresses (Ientile et al., 2007) and, in turn, 
activates NF-B signaling by stimulating the polymerization 
Figure 1.  TG2 deficiency reduces BLM-induced pulmonary inflammation and fibrosis. (A–C) Representative photographs of lungs from WT and 
TG2/ mice 21 d after intratracheal instillation of BLM (1.5 mg/kg) or PBS. Sections were stained with H&E (A) or Masson-trichrome (B). Pulmonary col-
lagen content of the lungs was determined by the Sircol assay (C). (D–F) Levels of IL-6 (D), MCP-1 (E), and MCP-3 (F) in BALF of WT and TG2/ mice after 
BLM-exposure were determined by ELISA. (G–J) Inflammatory cells in BALF from WT B6 and TG2/ mice. BLM-exposed mice were sacrificed to harvest 
BALF on the indicated days. Numbers of total cells (G), lymphocytes (H), macrophages (I), and neutrophils (J) in BALF were determined by flow cytometric 
analysis. Data represent means ± SD of three independent determinations with BALF or lung tissues, and n = 5 (A–C) or n = 3 mice/group for each time 
point (D–J).JEM Vol. 208, No. 8 
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expression of key cytokines and chemokines on day 3 in the 
lungs of WT mice, but not in TG2/ mice (Fig. S1). In-
creased production of cytokines and chemokines in WT mice 
compared with TG2/ mice were mirrored in the inflam-
matory cell recruitment in BALF. Flow cytometric analysis of 
the cells present in BALF revealed that BLM-treated WT 
mice exhibited gradual increases in the numbers of total in-
flammatory cells (Fig. 1 G), lymphocytes (Fig. 1 H), macro-
phages (Fig. 1 I), and neutrophils (Fig. 1 J) over a 10-d period, 
whereas significantly fewer cells were recruited to the lungs 
of the TG2/ mice (Fig. 1, G–J). Although the initial recruit-
ment of neutrophils 1 d after BLM instillation was compara-
ble in WT and TG2/ mice (Fig. 1 J), secondary neutrophilic 
infiltration was observed only in the WT mice (Fig. 1 J).
TG2-mediated IL-6 production triggers a Th17 response 
after BLM-induced lung injury
IL-6 is a key stimulator of Th17 cell differentiation (Weaver   
et al., 2007; McGeachy and Cua, 2008; Korn et al., 2009), and 
the role of Th17 cells in the immune response that follows 
pulmonary infection is well established (Aujla et al., 2007; 
Korn et al., 2009). We tested whether TG2-mediated IL-6 se-
cretion contributed to Th17 differentiation in lungs damaged 
by noninfectious injury (caused by BLM treatment). Num-
bers of CD4+ T cells in BALF, which constitute 40–70% of 
the total BALF T cell population, increased at days 5, 7, and 
10 (unpublished data). WT mice displayed 6-fold higher 
percentages and numbers of CD4+ IL-17+ T cells (hereafter 
inflammatory amplification in the lung. Moreover, we sepa-
rately  showed  that  the  activation  of TG2  in  fibroblasts 
(downstream of TGF-) is important during the effector 
phase of fibrogenesis. TG2 may therefore represent a useful 
therapeutic target.
RESULTS
TG2 mediates inflammatory cell recruitment and fibrosis  
in the BLM-treated lung
To explore the role of TG2 in the inflammation and fibrosis 
caused by noninfectious lung injury, we used a mouse BLM-
induced pulmonary fibrosis model. WT C57BL/6 (B6) and 
TG2/ mice were exposed to BLM by intratracheal instilla-
tion and sacrificed 21 d later. Histopathological examination 
of the lungs of BLM-treated TG2/ mice revealed markedly 
reduced inflammatory cell infiltration (Fig. 1 A) and collagen 
deposition (Fig. 1 B) compared with WT animals. A Sircol   
assay revealed significantly decreased total lung collagen con-
tent  in  BLM-treated TG2/  mice  compared  with WT 
controls (Fig. 1 C). To evaluate the factors responsible for ini-
tiating pulmonary inflammation, we measured the levels of 
cytokines  and  chemokines  in  bronchoalveolar  lavage  fluid 
(BALF). Notably, IL-6 was detected (by ELISA) in BALF 
from WT mice, but not from TG2/ mice, 3 d after BLM 
treatment (Fig. 1 D). BALF levels of both MCP-1 and MCP-
3 were higher in WT mice compared with TG2/ animals 
(Fig. 1, E and F). Semiquantitative RT-PCR analyses further 
showed  that  BLM  treatment  significantly  increased  the   
Figure 2.  BLM-mediated pulmonary in-
jury triggers a Th17 response. WT B6 and 
TG2/ mice received an intratracheal instilla-
tion of BLM (1.5 mg/kg) and were sacrificed to 
harvest BALF on the indicated days. Cells from 
BALF were stimulated with PMA and ionomycin 
and intracellular cytokines were detected by 
flow cytometric analysis. (A and B) Numbers of 
CD4+ cells producing IL-17 (A) or IFN- (B) in 
BALF of BLM-exposed WT B6 and TG2/ mice. 
(C) The percentages of CD4+ cells producing  
IL-17 or IFN- in BALF and draining lymph 
nodes (DLN) of WT B6 and TG2/ mice were 
determined by flow cytometric analysis 10 d 
after BLM exposure. Dot plots are gated on 
CD4+ T cells. (D–H) BLM-exposed WT B6 mice 
were treated with IL-17RA-Fc or isotype control 
for 10 d (100 µg/mouse/day, i.p.). IL-17 levels 
(D) and the numbers of CD4+IL-17+ cells (E), 
total cells (F), and neutrophils (G) were deter-
mined by ELISA and flow cytometry, respectively.   
(H) BLM-exposed mice were treated with  
IL-17RA-Fc or isotype control for the times indi-
cated. Quantitative analysis of the fibrotic area 
by H&E and Masson’s trichrome staining was 
performed 21 d after instillation of BLM. Data 
represent means ± SD of three independent 
determinations with BALF or lung tissues from 
n = 5 (H) or n = 3 mice/group for each time 
point (A–G).1710 TG2 triggers Th17 responses in pulmonary fibrosis | Oh et al.
IL-6  in  a TG2-dependent  manner,  in  response  to  BLM- 
induced tissue injury. To test this, we evaluated IL-6 expres-
sion in the lungs of WT B6 mice 2–3 d after BLM treatment. 
Basal IL-6 expression levels in the lung were low and in-
creased by BLM treatment. Dense immunoreactive foci were 
localized in the pulmonary epithelial cells, particularly in the 
round-shaped type II epithelial cells that expressed prosurfac-
tant protein-C (pro-SP-C; Fig. 4 A). TG2-dependent IL-6 
production from pulmonary epithelial cells was evaluated 
using purified epithelial cells. Sort-purified primary mouse lung 
epithelial cells (MLECs; purity > 90%; Fig. 4 B, left) from WT 
and TG2/ mice were treated with BLM. Treatment with 
BLM for 48 h increased secretion of IL-6 by BLM-treated 
primary MLECs from WT, but not TG2/, mice (Fig. 4 B, 
right). IL-6 levels in the culture supernatants of BLM-treated 
primary mouse lung fibroblasts (MLFs) were not greater than 
in PBS-treated controls of either mouse strain (Fig. 4 B, right). 
This selective responsiveness of epithelial cells was corrobo-
rated by the fact that BLM stimulated TG2 activity in primary 
MLECs, but not primary MLFs, as evaluated by Western blot-
ting,  ELISA,  and  fluorescence  microscopy  in  conjunction 
with biotinylated pentylamine incorporation (Fig. S3, A–C). 
TG2-mediated IL-6 production from MLECs was confirmed 
by the addition of the TG2 inhibitor cysteamine (CyM). IL-6 
production from WT MLECs was inhibited by CyM in a 
dose-dependent manner (Fig. 4 C).
referred to as IL-17 instead of IL-17A) at days 7, 10, and 13 
after BLM treatment than did TG2/ mice (Fig. 2, A and C). 
Thirty to forty percent of IL-17+ cells also expressed IL-17F, 
whereas all IL-17F+ cells coexpressed IL-17 (Fig. S2). Numbers 
of CD4+ IFN-+ T cells in WT mice were approximately 
twofold higher than in TG2/ mice (Fig. 2, B and C). More-
over, IL-17 levels in BALF correlated with CD4+ IL-17+ T cell 
numbers and peaked 13 d after BLM treatment (Fig. 2 D).
To evaluate the essential role of IL-17 in inflammatory 
cell recruitment after exposure to BLM, we treated mice be-
tween days 0 and 10 with IL-17RA-Fc, which can block both 
IL-17 and IL-17F (Kuestner et al., 2007). IL-17RA-Fc treat-
ment decreased BALF levels of IL-17 (Fig. 2 D) and numbers 
of CD4+ IL-17+ T cells (Fig. 2 E), as well as numbers of total 
inflammatory cells (Fig. 2 F) and neutrophils (Fig. 2 G). We 
next evaluated the effect of IL-17RA-Fc on the development 
of fibrosis. BLM-exposed mice treated with IL-17RA-Fc 
between days 0 and 10 exhibited reduced fibrosis compared 
with isotype control-treated animals (days 0 to 21) and a simi-
lar or greater reduction than animals treated with IL-17RA-Fc 
between days 0 and 21 (Fig. 2 H). This suggests that the pro-
duction of IL-17 and/or IL-17F after exposure to BLM is 
important in the pathogenesis of lung injury, predominantly 
during the initial inflammatory phase. This hypothesis was 
confirmed by the finding that mice treated with IL-17RA-Fc 
between days 11 and 21 displayed similar or higher levels of 
fibrosis to/than those treated with isotype control between 
days 0 and 21 (Fig. 2 H). Thus, IL-17RA-Fc was more effective 
at blocking fibrosis during the first half of the treatment period.
The critical role of IL-6 during BLM-induced Th17-
mediated  pulmonary  inflammation  and  fibrosis  was  con-
firmed  by  blocking  with  anti-IL-6  antibodies. Treatment 
between days 0 and 10 decreased the numbers of both total 
inflammatory cells and CD4+ T cells by half compared with 
isotype controls (Fig. 3, A and B). The reduction in CD4+ 
IL-17+ T cell numbers by anti-IL-6 antibody treatment was 
more marked: less than 15% of those in isotype control-treated 
mice (Fig. 3 C). This reduced inflammation was reflected in the 
decreased pulmonary fibrosis of these mice at 21 d after BLM 
instillation compared with isotype controls (Fig. 3, D and E).
Pulmonary epithelial cells are responsible for TG2-mediated 
IL-6 secretion after BLM treatment
TG2 is a ubiquitous enzyme expressed in both parenchymal 
cells and inflammatory cells. Innate immune cells, such as 
macrophages, are known to secrete inflammatory cytokines (in-
cluding IL-6) that initiate acute inflammation after tissue in-
jury. Moreover, TG2 activity in inflammatory cells, but not 
endothelial cells, was crucial to the pathogenesis of athero-
sclerosis induced by a high-fat diet in LDL receptor-deficient 
mice (Boisvert et al., 2006). However, in our study, BALF 
IL-6 levels peaked 3 d after BLM treatment (Fig. 1 D) and did 
not correlate with numbers of infiltrating inflammatory cells 
(Fig. 1, G, H, and J), suggesting that innate immune cells may 
not be the primary source of IL-6 in our model. We hypothe-
sized that lung epithelial cells or fibroblasts may instead produce 
Figure 3.  IL-6 blocking reduces pulmonary inflammation, Th17 
responses, and fibrosis induced by BLM. (A–C) Inflammatory cells in 
BALF were harvested 8 d after BLM exposure. BLM-exposed WT B6 mice 
were treated with blocking anti–IL-6 mAb or isotype-control twice weekly, 
beginning 1 d before BLM treatment (100 µg/mouse, i.p.). Numbers of 
total cells (A), CD4+ T cells (B), and CD4+ T cells producing IL-17 (C) in 
BALF were determined by flow cytometry. (D) A representative photograph 
of lungs from isotype control– and anti–IL-6 mAb–treated WT B6 mice  
21 d after BLM exposure. Sections were stained with Masson’s trichrome.  
(E) Quantitative analysis of the fibrotic area by H&E and Masson’s tri-
chrome staining was performed 21 d after instillation of BLM. Data repre-
sent means ± SD of two independent determinations with BALF or lung 
tissues from n = 5 mice/group.JEM Vol. 208, No. 8 
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suggest that BLM induced secretion of IL-6 by lung epithe-
lial cells through activation of a TG2-dependent NF-B sig-
naling pathway.
Defective Th17 responses in TG2/ mice is not  
T cell intrinsic
Because TG2 is also expressed in T cells, the failure to trigger 
a Th17 response in TG2/ mice may reflect a defect in the 
differentiation of TG2/ T cells. To assess this, we induced 
the Th17 differentiation of lymphocytes isolated from WT 
and TG2/ mice by addition of IL-6 and TGF- to the 
Next, the role of NF-B activation in TG2-induced IL-6 
secretion by pulmonary epithelial cells was evaluated. BLM 
treatment increased NF-B reporter activity in primary 
MLECs from WT, but not TG2/, mice (Fig. S4 A). NF-B 
activity was not altered in primary MLFs from either mouse 
strain (Fig. S4 B). Levels of phospho-p65 in the lungs of 
WT mice increased 3 d after exposure to BLM and were 
higher than those in TG2/ mice at the same time point 
(Fig. S4 C). Moreover,  the  secretion  of  IL-6  by  primary 
MLECs from WT mice was suppressed by treatment with 
the NF-B inhibitor Bay-11-7082 (Fig. 4 D). These data 
Figure 4.  BLM induces secretion of IL-6 from lung epithelium. (A) Immunofluorescence staining of IL-6 production (green) from pro-SP-C (red)–
expressing type II epithelial cells in the lungs of BLM-exposed WT B6 mice. Nuclei were counterstained with DAPI (blue). (B) Lung epithelial cells express-
ing pro-SP-C were sort-purified (top). IL-6 levels in culture supernatants of sort-purified primary MLECs and primary MLFs from WT B6 mice as 
determined by ELISA. Cells (2 × 104) were treated with BLM (5 µg/ml) for the times indicated. (C) Primary MLECs from WT B6 mice were treated with BLM 
(5 µg/ml) in the presence of the TG2 inhibitor CyM or PBS. (D) Effect of Bay-11-7082, a chemical inhibitor for NF-B, on BLM-induced IL-6 secretion in 
primary MLECs from WT B6 mice. (E) Th17 differentiation of CD4+ T cells induced by culture supernatants of primary MLECs. Lymphocytes isolated from 
WT B6 mice were stimulated with anti-CD3 and anti-CD28 for 3 d in the presence of culture supernatants of primary MLECs from WT and TG2/ mice 
treated with PBS or BLM. As indicated, anti–IL-6 (10 µg/ml) or anti–TGF- (10 µg/ml) antibodies were added to the culture. After restimulation with PMA 
and ionomycin, percentages of CD4+ T cells expressing IL-17 or IFN- were determined by flow cytometry. (F) IL-6 levels in the culture supernatants of 
lung macrophages and primary MLECs were determined by ELISA. Lung macrophages (5 × 104) and primary MLECs (2 × 104) from WT B6 and TG2/ mice 
treated with PBS, LPS (1 µg/ml), or BLM (5 µg/ml) for 48 h. (B–F) Data represent means ± SD, based on three independent determinations using samples 
from n = 3 cell cultures. *, P ≤ 0.05; **, P ≤ 0.005. Representative data from three independent determinations are shown.1712 TG2 triggers Th17 responses in pulmonary fibrosis | Oh et al.JEM Vol. 208, No. 8 
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growth medium. We detected no difference between the per-
centages of CD4+ T cells expressing IL-17 in WT and TG2/ 
mice  (Fig.  S5 A).  Moreover, TGF-–treated T  cells  from 
TG2/ mice displayed similar in vitro differentiation into 
regulatory T cells as did T cells from WT mice (Fig. S5 B). 
These findings show that defects in Th17 differentiation in 
TG2/ mice are not T cell intrinsic. The importance of   
T cell-extrinsic factors for Th17 differentiation after BLM-
induced injury was confirmed by applying culture super-
natant from BLM-stimulated primary MLECs from WT and 
TG2/ mice to activated CD4+ T cells from WT mice. 
Incubation with culture supernatants from WT MLECs, but 
not from TG2/ MLECs, increased the Th17 differentiation 
of CD4+ T cells. These effects were abrogated by the addition 
of anti–IL-6 or anti–TGF- antibodies to the culture me-
dium (Fig. 4 E).
The TG2-dependency of IL-6 production in pulmonary 
epithelial cells and subsequent Th17 differentiation were the 
characteristic features of BLM-induced lung injury. In con-
trast, exposure to LPS, an infection-associated stimulus, in-
duced secretion of IL-6 by primary MLECs and macrophages 
from both WT and TG2/ mice (Fig. 4 F), and culture super-
natants from LPS-stimulated primary MLECs both from 
WT and TG2/ mice induced Th17 differentiation of CD4+ 
T cells (unpublished data). Activation of epithelial TGF-, 
which  contributes  to Th17  differentiation,  after  treatment 
with either BLM or LPS, was also independent of TG2 ex-
pression (Fig. S6 and data not shown). These results indicate 
that epithelial TG2 activity is crucial for IL-6 secretion and 
Th17 responses in noninfectious BLM-induced injury.
BLM treatment induced Th17 differentiation in the lung
In this study, we hypothesize that TG2 expressed by pulmo-
nary epithelial cells responded to BLM treatment and induced 
Th17 differentiation, leading to inflammatory cascade and fi-
brosis. We questioned how the tissue microenvironment pro-
duced by activated pulmonary epithelial cells could lead to 
Th17 differentiation. One possibility is that the local micro-
environment in the lung has been translated into tissue den-
dritic cells. Educated dendritic cells migrate into the draining 
lymph nodes and activate and differentiate naive T cells; dif-
ferentiated Th17 cells then migrate to the inflamed lung.   
Another possibility is that the tissue microenvironment in   
the lung directly induces T cell activation and differentiation. 
To evaluate these possibilities, we intratracheally administered 
BLM, followed by application of FTY720. FTY720, a super-
agonist of sphingosine-1-phosphate receptor 1, inhibits the 
egress of T cells from, but not migration of tissue dendritic 
cells from inflamed tissue to, lymph nodes (Worbs et al., 2006). 
If BLM-induced T cell activation and differentiation occurs 
in the draining lymph nodes, then differentiated Th17 cells 
would be expected to accumulate there and would not mi-
grate into the lung in the presence of FTY720. FTY720 
treatment between days 3 and 7 (analyzed on day 7), between 
days 3 and 8 (analyzed on day 8), and between days 5 and 8 
(analyzed on day 8) did not show accumulation of differenti-
ated Th17 cells in the draining lymph nodes compared with 
PBS-treated controls (Fig. 5 A). FTY720 treatment also in-
hibited pulmonary Th17 differentiation, suggesting a lack of 
migration of unactivated T cells into the lung after FTY720 
treatment (Fig. 5 B). Time-scheduled treatment of FTY720 
suggested that T cell migration and Th17 differentiation in 
the lung occur primarily between days 5 and 8 after BLM in-
stillation. A reduction in the numbers and percentage of 
CD4+IL-17+ T cells in the lung according to the serial short-
ening of the treatment duration of FTY720 did not lead to 
proportionate  accumulation  of  these  cells  in  the  draining 
lymph nodes (Fig. 5 C).
We next evaluated T cell proliferation and Th17 differen-
tiation in the lung and draining lymph nodes during this pe-
riod.  CFSE-labeled Thy1.1+CD4+ T  cells  were  adoptively 
transferred into B6 (Thy1.2) mice 1 d after BLM instillation. 
Recipient mice received 300 µg of depleting anti-Thy1.2 
antibody on days 1 and 2. Donor CD4+ T cells in the lung 
showed proliferation and Th17 differentiation from day 5 
after BLM instillation. A sequential increase in the per-
centages and numbers of donor Thy1.1+CD4+ T cells and 
CD4+IL-17+ cells in the lung was evident from days 5–8 after 
BLM instillation (Fig. 5 D). In contrast, CD4+ T cell prolifera-
tion in the draining lymph nodes and spleens of BLM- 
administered mice was comparable to that in PBS-treated 
control animals, reflecting homeostatic proliferation of these 
cells in the lymphoid organs of T cell–depleted hosts (Fig. 5 E 
and not depicted). Notably, homeostatic proliferation did not 
Figure 5.  Th17 cells proliferate and differentiate in the lung. (A and B) WT B6 mice received BLM intratracheally (1.5 mg/kg). BLM-exposed mice 
were treated with PBS or FTY720 (2 mg/kg/day, i.p.) between days 3 and 7 (analyzed on day 7), between days 3 and 8 (analyzed on day 8), and between 
days 5 and 8 (analyzed on day 8). Mice were sacrificed and BALF and draining lymph nodes (DLN) harvested on the days noted above. The percentages of 
CD4+ cells producing IL-17 or IFN- in draining lymph nodes (DLN; A) and BALF (B) were determined by flow cytometric analysis. (C) BLM-exposed WT B6 
mice were treated with PBS or FTY720 (2 mg/kg/day, i.p.) at day 5, 6, or 7 after BLM-exposure. Numbers and percentages of CD4+ cells producing IL-17 in 
BALF and DLN were determined by flow cytometric analysis 8 d after BLM exposure. (D and E) WT B6 (Thy1.2) mice received BLM intratracheally (1.5 mg/kg). 
On the next day, BLM-exposed mice were adoptively transferred with CFSE-labeled Thy1.1+ CD4+ T cells (5 × 106 cells). To deplete endogenous T cells, 
anti-Thy1.2 antibody (30-H12; 300 µg/mouse) was administered i.p. to recipient mice on days 1 and 2 of BLM treatment. (D) Mice were sacrificed to 
harvest leukocytes from lungs on the days indicated. The percentages of donor Thy1.1+ CD4+ cells producing IL-17 were determined by flow cytometric 
analysis. (E) The percentages of donor Thy1.1+ CD4+ cells producing IL-17 in lungs and draining lymph nodes (DLN) of recipient mice were determined by 
flow cytometric analysis 8 d after PBS or BLM exposure. (F and G) WT B6 (Thy1.2) mice were adoptively transferred with CFSE-labeled naive phenotype 
Thy1.1+ CD4+ T cells (5 × 106 cells) 1 d after BLM exposure. Some mice received FTY720 10 h before naive phenotype Thy1.1+ CD4+ T cell transfer. Percent-
ages (F) and numbers (G) of donor Thy1.1+ CD4+ cells producing IL-17 in lungs and DLN of recipient mice were determined by flow cytometric analysis 8 d 
after PBS or BLM exposure. (C and G) Data represent means ± SD of three independent determinations with BALF or lung tissues from n = 5 mice/group.
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recruitment in these chimeras (Fig. 6, A and B). Thus, epithe-
lial TG2 induced an inflammatory cascade, comprising Th17 
induction and TGF- activation.
We next evaluated the role of fibroblast-derived TG2 in 
the effector phase of fibrogenesis. TGF- treatment increased 
the expression and cross-linking of the ECM protein fibro-
nectin in primary MLFs from WT mice, but not from TG2/ 
animals (Fig. S8, A and B). Furthermore, TGF-–mediated 
increases in TG2 activity, fibronectin expression, and cross-
linking, as well as -SMA expression in IMR90 human   
induce Th17 differentiation in either the lung or the draining 
lymph  nodes  (Fig.  5  E). Transfer  of  sort-purified Thy1.1+ 
CD4+CD45RBhi (naive phenotype) cells also revealed com-
parable donor CD4+ T cell proliferation and Th17 differen-
tiation in the lung (Fig. 5 F). The effect of FTY720 on naive 
phenotype  CD4+ T  cell  recruitment  into  the  lung  was 
evaluated by treating with FTY720 during the whole ex-
perimental period. Increased numbers of donor CD4+ and 
CD4+IL-17+ T cells after BLM treatment were blocked by 
FTY720 treatment (Fig. 5 G), indicating that migration of 
unactivated T cells into the lung was blocked by FTY720 
treatment. In the draining lymph nodes, FTY720 treatment, 
again, did not lead to the accumulation of donor CD4+ and 
CD4+IL-17+ T cells after naive phenotype CD4+ T cell trans-
fer and BLM treatment (Fig. 5 G).
Epithelial TG2 is critical for Th17 responses and fibrosis
To further confirm the role of the lung epithelium and epi-
thelial TG2 in Th17 responses in vivo, BM-chimeric mice 
were exposed to BLM, and numbers of cells in BALF were 
analyzed 10 d later. WT mice reconstituted with TG2/ BM 
(BMTG2/→WT) exhibited a similar percentage of CD4+ 
IL-17+ cells to WT control chimeras (BMWT→WT), whereas 
TG2/ mice reconstituted with WT BM (BMWT→TG2/) 
displayed reduced percentages of CD4+ IL-17+ cells that were 
comparable to those in  TG2/ control chimeras (BMTG2/→
TG2/; Fig. 6 A). Th17 differentiation in the chimeras cor-
related with BALF IL-6 levels (Fig. 6 B). Histopathological 
analysis 21 d after BLM treatment revealed fewer inflamma-
tory cells and reduced collagen deposition in the lungs of 
chimeras in which  TG2/ mice were the recipients (BMWT→
TG2/ and BMTG2/→TG2/), compared with those 
in which WT mice were the recipients (BMWT→WT and 
BMTG2/→WT; Fig. 6 C). Similarly, fibrosis, expressed as 
percentage of fibrotic tissue (as assessed by Masson’s trichrome 
staining; Fig. 6 D), and collagen content (Fig. 6 E) were re-
duced in the TG2/ host chimeras (BMWT→TG2/ and 
BMTG2/→TG2/). Collectively, these results indicate that 
nonhematopoietic (i.e., epithelial) TG2 is important for gen-
eration of the local Th17 response and subsequent fibrosis 
that follows BLM-induced tissue injury.
Fibroblast-derived TG2 mediates  
TGF-–induced fibrogenesis
Chronic inflammation induces TGF- activation, which, in 
turn, dampens the inflammatory response (Serhan and Savill, 
2005; Li et al., 2006). We found the bioactivity of TGF- in 
the  BALF  of  BLM-exposed WT  mice  to  be  significantly 
higher than that in similarly treated TG2/ mice (Fig. S7 A). 
This increase displayed similar kinetics to that of inflamma-
tory cell infiltration (Fig. 1, G–J), peaking at day 10 after BLM 
exposure (Fig. S7 A). Consistent with these findings, the bio-
activity of TGF- in the BALF of WT mice reconstituted 
with TG2/ BM (BMTG2/→WT) was markedly higher 
than that in  TG2/ mice reconstituted with  WT BM (BMWT→
TG2/; Fig. S7 B), a response that mirrors inflammatory cell 
Figure 6.  Chimeric mice with TG2/ recipients exhibit diminished 
pulmonary inflammation and fibrosis in response to BLM. BM chime-
ras were prepared by irradiation of WT B6 or TG2/ mice, followed by  
T cell–depleted BM cell reconstitution (BMWT→WT, BMTG2/→WT, 
BMWT→TG2/, and BMTG2/→TG2/). (A) The percentage of CD4+ 
IL-17+ cells in BALF of the chimeras was determined by flow cytometric 
analysis 10 d after BLM exposure. (B) IL-6 levels in BALF from chimeras  
3 d after BLM exposure was determined by ELISA. (C) Representative photo-
graphs of lungs from chimeras are shown. Lung tissues were prepared  
21 d after BLM instillation and stained with Masson’s trichrome.  
(D and E) Quantitative analysis of fibrosis was performed using Masson’s 
trichrome staining (D) and pulmonary collagen content (Sircol assay; E)  
21 d after BLM exposure. Data represent means ± SD of three indepen-
dent determinations with BALF or lung tissues from n = 5 mice/group.JEM Vol. 208, No. 8 
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cross-links ECM proteins, TG2 has recently been shown to 
play an active role in inflammation (Kim, 2006). Here, we 
used a BLM-induced pulmonary fibrosis model to demon-
strate that activation of epithelial TG2 induces a Th17 in-
flammatory  response  in  the  lung  that  causes  excessive 
wound healing and fibrosis through activation of fibroblast 
TG2. We have shown that TG2 is a critical regulator of in-
flammatory and repair responses and links noninfectious 
tissue injury and fibrogenesis.
In this study, we identified a critical role for epithelial 
cell–derived TG2 in inducing the secretion of IL-6, and con-
sequent Th17 inflammation, after BLM-induced lung damage. 
During protective immunity against pathogens and auto-
immune tissue destruction, IL-6 secreted by innate immune 
cells is thought to activate Th17 differentiation (Weaver et al., 
2007; McGeachy and Cua, 2008; Korn et al., 2009). However, 
we found that WT lung epithelial cells treated with BLM 
produced IL-6, and that soluble factors secreted from BLM-
exposed  lung  epithelial  cells  induced Th17  differentiation. 
These effects were blocked by anti–IL-6 and anti–TGF- 
antibodies, indicating that IL-6 and TGF- are the primary 
cytokines involved in Th17 differentiation after BLM-induced 
lung injury. Treatment with a blocking anti–IL-6 antibody in 
vivo also confirmed the critical role of IL-6 in Th17-mediated 
pulmonary inflammation and fibrosis.
In  contrast,  culture  supernatants  from  BLM-stimulated 
lung epithelial cells from TG2/ mice contained only low 
levels of IL-6 and did not support Th17 differentiation. The 
critical involvement of epithelial TG2 in Th17 responses in 
vivo was further confirmed in our BM chimera study. As 
anticipated, WT recipients produced greater amounts of IL-6 
than TG2/ recipients. In WT mice reconstituted with WT 
or TG2/ BM cells, 30–50% of CD4+ T cells produced IL-17, 
whereas very few CD4+ IL-17+ cells were present in TG2/ 
recipients. Although this disparity may stem from differences 
in the amount of IL-6 secreted by epithelial cells, IL-6 pro-
duction is not always TG2-dependent. In an LPS-induced 
septic  shock  model,  both WT  and 
TG2/  mice  rapidly  secreted  large 
amounts of IL-6 and IFN- (Falasca 
et al., 2008). In the present study, LPS 
fibroblasts, were inhibited by the TG2 inhibitor CyM (Fig. S9, 
A and B). These results indicate that TG2 is a downstream   
effector of TGF-a  responses in fibroblasts during wound 
healing/fibrosis.
Inhibition of TG2 during either the early or late phases 
ameliorates lung fibrosis
We have shown that TG2 is very important in both the initial 
inflammatory  phase  and  subsequent  fibrosis  phase  in  our 
BLM-induced lung fibrosis model. Because clinical cases of 
pulmonary fibrosis are characterized by both inflammation 
and wound healing/fibrosis, and the inhibition of either pro-
cess alone using antiinflammatory or antifibrotic drugs does 
not adequately reduce disease progression (Rogliani et al., 
2008; Kim and Meyer, 2008; du Bois, 2010), the distinct roles 
of TG2 in both processes are intriguing and warrant further 
evaluation. We assessed the effects of inhibiting TG2 during 
the early and late phases on the development of lung fibrosis. 
BLM-exposed mice treated with CyM between days 0 and 
10 exhibited markedly reduced leukocyte infiltration and 
fibrosis, comparable to mice treated with CyM between days 
0 and 21, as evaluated by histopathological analyses (Fig. 7 A), 
measurements of fibrotic areas (Fig. 7 B), and total lung colla-
gen content (Fig. 7 C). Mice treated with CyM between days 
11 and 21 also exhibited significantly reduced fibrosis relative 
to animals treated with vehicle between days 0 and 21 (Fig. 7, 
A–C). We also observed significantly reduced fibrosis in mice 
treated with CyM between days 15 and 28 compared with 
animals treated with vehicle alone between days 15 and 28 in 
a 28-d BLM-induced lung fibrosis model (Fig. S10).
DISCUSSION
A causal role for TG2 in pathological increases in collagen 
deposition in the kidney and liver has been proposed; specifi-
cally, TG2 is considered to be important in the development 
of fibrosis in these organs (Shweke et al., 2008; Elli et al., 
2009). Originally described as an enzyme that irreversibly 
Figure 7.  Inhibition of TG2 by CyM  
during either the early or late phase  
effectively reduces lung fibrosis induced 
by BLM. (A) Representative photographs of 
lungs from WT mice 21 d after exposure to 
BLM. BLM-exposed mice were treated with 
PBS or CyM (40 mg/kg/day, i.p.) during the 
early phase (days 0–10), late phase (days 11–21), 
or for all 21 d. Sections were stained with 
Masson’s trichrome. (B and C) Quantitative 
analysis of fibrotic area (B) and pulmonary 
collagen content (C) 21 d after BLM exposure. 
Data represent means ± SD of three indepen-
dent determinations with lung tissues from  
n = 5 mice/group for each time point.1716 TG2 triggers Th17 responses in pulmonary fibrosis | Oh et al.
epithelial tissue injury. The characteristic tissue microenviron-
ment of the lung, or induced lymphoid-like structures in this 
tissue, may be responsible for this. The importance of other 
mucosal tissues for activation of naive T cells warrants further 
investigation. Such alternate T cell activation pathways may 
provide new methods for regulation of immune responses.
Th17 lymphocytes mediate lung inflammation by regu-
lating neutrophil recruitment (Aujla et al., 2007; Weaver et al., 
2007; McGeachy and Cua, 2008; Korn et al., 2009). Here, we 
demonstrated that induction of a Th17 response is critical 
during the initial inflammatory cascade that follows intratracheal 
BLM instillation, consistent with recent works (Sonnenberg   
et al., 2010; Wilson et al., 2010). Recruitment of inflamma-
tory cells, most notably neutrophils, paralleled this Th17 
response, whereas blocking IL-17 signaling through the ad-
ministration of IL-17RA-Fc between days 0 and 10 greatly 
reduced inflammatory cell/neutrophil recruitment. IL-17RA-Fc   
treatment also reduced lung fibrosis measured at day 21, 
consistent  with  previous  studies  that  neutrophil  activation 
and elastase production are critical to the pathogenesis of 
BLM-induced lung fibrosis (Jones et al., 1998; Chua et al., 
2007). However, treatment with IL-17RA-Fc during the late 
phase (days 11 to 21) increased fibrosis by 1.4-fold compared 
with isotype control-treated mice. Initial amplification of the 
inflammatory response and subsequent negative regulatory 
effects of IL-17 were previously reported in allergic asthma 
(Schnyder-Candrian et al., 2006). IL-17 secreted by  T cells 
has been shown to provide a help signal during pulmonary 
epithelial repair (Braun et al., 2008). This pathway may con-
tribute to the responses we observed in this study. Indeed, an 
essential role for IL-17A in lung inflammation, but not fibro-
sis, has also been reported in another noninfectious injury 
model of experimental silicosis (Lo Re et al., 2010).
In addition to the dominant role of IL-17, other cytokines 
such as IFN-, IL-1, IL-13, TGF-, IL-10, and IL-4 have 
also been implicated in the BLM-induced pulmonary fibrosis 
model (Wilson et al., 2010). IFN- was reported to have a 
critical role during BLM-induced pulmonary fibrosis (Chen 
et al., 2001), and we also found that numbers of CD4+ IFN-+ 
T cells in WT mice were approximately twofold higher 
than in TG2/ mice. However, there was a dramatic reduc-
tion in CD4+ IL-17+ T cells compared with CD4+ IFN-+  
T cells in TG2/ mice. Nonetheless, our data showed that 
the reduction of pulmonary fibrosis in IFN-/ mice was 
not dramatic compared with TG2/ mice (unpublished data), 
and blocking the IL-17 signaling pathway through IL-17RA-Fc 
treatment almost completely abrogated lung inflammation, 
leading us to consider that IL-17 rather than IFN- plays a 
predominant role during the initial inflammation after BLM 
instillation. A recent work showing the predominant role of 
IL-17A in the BLM-induced lung fibrosis model (Wilson 
et  al.,  2010)  also  supports  our  contention. These  authors 
showed that IL-17A–driven fibrosis is facilitated by IFN-, 
and that the reduced fibrotic response in IFN-/ mice was 
associated with decreased IL-17A expression and reduced cir-
culating neutrophils (Wilson et al., 2010), which is preferable 
induced the secretion of IL-6 from both lung epithelial cells 
and  lung  macrophages  in  a TG2-independent  manner. 
Bacterial molecules activated epithelial and inflammatory 
cells directly through TLRs in a process that seemed to be 
TG2 independent.
In conclusion, TG2-dependent epithelial IL-6 production 
is a defining characteristic of noninfectious epithelial injury. 
TG2 serves as a stress sensor in epithelial cells (Ientile et al., 
2007) and transduces epithelial damage into IL-6 secretion, 
which provides the signal for inflammatory Th17 differentia-
tion after noninfectious injury. Epithelium-derived IL-6 may 
also modulate the local balance between Th17 and regulatory 
T cells, and thus influence immune homeostasis (Ivanov et al., 
2007). The role of TG2 in this context requires further inves-
tigation, especially under noninfectious conditions. Th17 cells 
have been implicated in various autoimmune diseases, in-
cluding multiple sclerosis (Kebir et al., 2007) and psoriasis   
(Di Cesare et al., 2009), and it will be interesting to deter-
mine whether the activation of TG2 promotes Th17 differ-
entiation in such diseases.
T cell activation and Th17 differentiation in the lung after 
BLM instillation requires further comment. In this study, we 
obtained an unexpected finding that CD4+ T cell prolifera-
tion and Th17 differentiation occurred primarily in the lung, 
not in the draining lymph nodes, after BLM-mediated pul-
monary epithelial injury. A long-standing immunological 
paradigm is the central sensitization of naive T cells in the 
lymphoid organs, which reflects the characteristic migratory 
pathway of naive T cells confined to these sites (Dailey, 1998). 
For this reason, CD4+ T cell activation and differentiation in 
the peripheral tissue is intriguing, and recent studies showing 
that naive T cells also migrate to peripheral tissues, including 
the lung (Cose et al., 2006; Staton et al., 2006), further con-
firm our data; adoptive transfer of naive phenotype CD4+ 
donor T cells revealed CD4+ T cell proliferation and Th17 
differentiation in the lung after BLM instillation, and FTY720 
treatment did not lead to accumulation of donor CD4+ and 
CD4+IL-17+ T cells in the draining lymph nodes. Immune 
activation and amplification in peripheral tissues is considered 
to be significant for perpetuating chronic inflammation; i.e., 
ectopic lymphoid structures in the joints in rheumatoid 
arthritis (Manzo and Pitzalis, 2007). Moreover, migration to 
and activation of naive tumor-specific CD8+ T cells inside the 
tumor tissue has warranted proposal of a new pathway, where 
naive T cells can be activated by interaction with tissue- 
resident cells (Thompson et al., 2010). In this study, naive 
CD8+ T cells were activated both by tumor cells themselves 
and by cross-presenting antigen-presenting cells within the 
tumor (Thompson et al., 2010). The nature of the tissue-
resident cells in the lungs of BLM-administered mice that 
provide such signals has not been determined. As is the case in 
tumor tissue, pulmonary epithelial cells themselves or cross-
presenting tissue-resident antigen-presenting cells may per-
form this function. Naive CD4+ T cell migration, activation, 
and differentiation in the inflamed lung may thus serve as a 
novel pathway of peripheral activation of naive T cells after JEM Vol. 208, No. 8 
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Seoul National University College of Medicine. All animal experiments were 
performed with the approval of the Institutional Animal Care and Use Com-
mittee at Seoul National University.
Induction of pulmonary fibrosis. Pulmonary fibrosis was induced by in-
tratracheal instillation with BLM (1.5 mg/kg, Nippon Kayaku, Japan) in   
50 µl PBS as described previously (Jones et al., 1998). A proportion of the mice 
were injected intraperitoneally with CyM (40 mg/kg/day; Sigma-Aldrich), 
recombinant murine IL-17RA-Fc (100 µg/mouse/day; R&D Systems) or 
control human IgG1 (100 µg/mouse/day; R&D Systems) suspended in PBS. 
To block IL-6 signaling, mice were injected intraperitoneally with blocking 
anti–IL-6 mAb (100 µg/mouse; eBioscience) or control Rat IgG1 (100 µg/
mouse; eBioscience) every 3 d, starting 1 d before receiving BLM treatment). 
To evaluate Th17 differentiation in the lung, BLM-exposed mice were treated 
with PBS or FTY720 (2 mg/kg/day, i.p.) during the periods indicated.
BM chimera. Recipient mice were lethally irradiated (950 rad whole-body 
irradiation in two split doses) and injected intravenously with T cell–depleted 
BM cells (3 × 106/mouse), as described previously (Surh et al., 1997). Reconsti-
tuted mice were used in the experiments 10 wk after BM cell transfer.
Donor CD4+ T cell analysis. WT B6 mice received an intratracheal instil-
lation of BLM (1.5 mg/kg). 1 d later, mice were injected with 5 × 106 puri-
fied and CFSE-labeled CD4+ T cells from B6.Thy1.1 lymph nodes via the 
tail vein. To deplete endogenous T cells, anti-Thy1.2 antibody (30-H12,   
300 µg/mouse) was administered i.p. to recipient mice on days 1 and 2 of 
BLM treatment. For the transfer of naive phenotype CD4+ T cells, cells from 
B6.Thy1.1 lymph nodes were labeled with APC-conjugated anti-CD4 and 
PE-conjugated anti-CD45RB. CD4+CD45RBhigh cells were purified using 
a FACS Aria cell sorter (BD) and subsequently labeled with CFSE.
Histopathology and immunofluorescence of lung tissue. Lung tissues 
were fixed in 4% paraformaldehyde, processed, and embedded in paraffin. 
Sections were stained with H&E for histopathological analysis or with 
Masson’s trichrome for the evaluation of collagen content and distribution. 
The extent of fibrosis was measured using the ProgRes CF system (Jenoptik). 
To investigate IL-6 expression in epithelial cells, lung tissue from BLM-exposed 
mice was stained with anti–IL-6 (R&D Systems) and anti–pro-surfactant 
protein-C (pro-SP-C; Millipore). Alexa Fluor 488–conjugated donkey anti–
goat IgG (Invitrogen) and Alexa Fluor 546–conjugated anti–rabbit IgG 
(Invitrogen) antibodies were used for visualization. Image acquisition and 
processing was performing using a confocal fluorescence microscope (Olympus) 
and FV10-ASW 2.0 Viewer (Olympus).
Collection of BALF. Bronchoalveolar lavage was performed with five 
1.0-ml aliquots of PBS through a tracheal cannula. To evaluate cytokine pro-
duction, BALF cells were harvested and restimulated with 50 ng/ml PMA 
and 1 µg/ml ionomycin (Sigma-Aldrich) for 4 h. For intracellular staining, 
brefeldin A (BD) was added during the final 2 h of stimulation. Cells were 
fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and 
incubated with anti-CD4, anti-CD8, anti-IL-17, and anti–IFN- antibodies 
(eBioscience). Intracellular cytokine levels were assayed by flow cytometry.
Collagen content measurement. The total collagen content of the left 
lung was measured by the Sircol collagen dye binding assay, according to the 
manufacturer’s instructions (Biocolor Ltd.).
Flow cytometry. BALF cells were incubated with mAbs to mouse CD4, 
CD8, B220, CD11c, CD11b, Gr1, and F4/80 that were conjugated to fluores-
cein, phycoerythrin, PerCP-Cy5.5, or allophycocyanin (eBioscience). Cells 
were analyzed using a FACSCalibur (BD) and FlowJo software (Tree Star).
Primary lung epithelial cells. The lungs were perfused with PBS and di-
gested with collagenase D (400 µg/ml; Invitrogen), dispase (50 µg/ml; Invit-
rogen), and DNase I (0.5 U/ml; Sigma-Aldrich) for 1 h at 37°C. Cells were 
for the dominant role of IL-17 in the BLM-induced lung fi-
brosis model.
In the BLM-treated lung, amplification of the initial in-
flammatory response as a result of Th17 polarization results in 
activation of TGF-, which would be expected to dampen 
local inflammation and facilitate the shift to fibrogenesis 
(Serhan and Savill, 2005; Li et al., 2006). TGF- acts as a fi-
brogenic switch that increases ECM synthesis and reduces the 
activity of ECM-degrading enzymes (Serhan and Savill, 2005; 
Li et al., 2006). It also induces expression of proteins that sta-
bilize the ECM, including plasminogen activator inhibitor-1 
and TG2 (Verderio et al., 2004). When intracellular TG2 is 
activated, it localizes to the marginal zone and is secreted 
(Gaudry et al., 1999). Extracellular TG2 acts as an ECM re-
modeler that increases the cross-linking of ECM molecules 
(Akimov and Belkin, 2001;  Verderio et al., 2004). Intriguingly, 
intracellular TG2 activity has been suggested to be critical in 
renal fibrosis after subtotal nephrectomy (Johnson et al., 1997). 
In the present study, we found that intracellular TG2 activity 
in fibroblasts mediated the majority of the fibrogenic effects 
of TGF-, including the synthesis of fibronectin and -smooth 
muscle actin. The fibrogenic effects of TGF- were decreased 
by the TG inhibitor CyM and were not observed in primary 
MLFs from TG2/ mice. Thus, we suggest that during the 
fibrogenesis of lung fibroblasts, activated TGF- exerts its   
effects in a primarily TG2-dependent manner.
The direct involvement of TG2 in the effector fibro-
genic pathway downstream of TGF- indicates that inhibi-
tion of TG2 may directly reduce fibrosis regardless of the 
presence or absence of active inflammation, a conclusion 
that is highly relevant to IPF, in which overt inflammation is 
not common (Kim and Meyer, 2008; Rogliani et al., 2008; 
du Bois, 2010). CyM treatment during the late phase alone 
in our BLM-induced lung fibrosis model significantly reduced 
lung fibrosis and collagen deposition. The much greater   
effect of CyM in mice treated during the early phase suggests 
that the inflammatory response is more dominant in BLM-
treated mice than in human IPF patients. Thus, TG2 inhibi-
tion may modulate two essential pulmonary fibrosis pathways 
simultaneously and TG2 itself may represent an ideal mo-
lecular target in IPF, and inhibitors specific for TG2 may be 
useful tools in the treatment of pulmonary fibrotic diseases 
including IPF. But despite all this, the BLM-induced lung 
fibrosis model is an inflammation-oriented fibrosis model 
that may not be an ideal representation of human IPF, and 
inflammation and subsequent fibrosis processes may con-
tinue even in the late phase of the disease model. Therefore, 
it would be better to use a more fibrosis-oriented model to dem-
onstrate the critical role of TG2 in inflammation-independent 
pulmonary fibrogenesis.
MATERIALS AND METHODS
Mice. B6 mice were obtained from The Jackson Laboratory. TG2/ mice 
(De Laurenzi and Melino, 2001) were backcrossed to B6 mice for 12 genera-
tions (N12). 8–12-wk-old male mice were used for experiments, and all 
mice, including WT B6, were bred and maintained at the animal facility of 1718 TG2 triggers Th17 responses in pulmonary fibrosis | Oh et al.
Western blots. Cells were harvested in a lysis solution containing 50 mM 
Tris/HCl (pH 7.6), 1% NP-40, 150 mM NaCl, 2 mM EDTA, and 100 µM 
PMSF in the presence of a protease inhibitor cocktail (Roche) and phospha-
tase inhibitor (Sigma-Aldrich). After incubation on ice for 30 min, cellular 
debris was removed by centrifugation (10 min, 4°C). Protein concentrations 
were assayed using the BCA protein assay reagent (Thermo Fisher Scientific). 
Total protein was resolved by SDS-PAGE, and then transferred to polyvinyli-
dene difluoride membranes. After blocking with 5% skim milk, membranes 
were probed with the appropriate antibody. Blots were developed with an 
enhanced  chemiluminescence Western  blotting  detection  system  (GE 
Healthcare). Antibodies used were as follows: anti-TG2 (Neomarker), anti-
p65 (Abcam), anti–phospho-p65 (Cell Signaling technology), anti–-smooth 
muscle actin (DAKO), anti-actin (Sigma-Aldrich), and anti-fibronectin (Santa 
Cruz Biotechnology, Inc.).
Statistical analysis. Statistical significance was analyzed using the Student’s 
t test. A p-value of <0.05 was taken to indicate statistical significance.
Online supplemental material. Fig. S1 shows semiquantitative RT-PCR 
analysis of cytokine and chemokine expression in the lungs of BLM-exposed 
mice. Fig. S2 shows that 30–40% of IL-17+CD4+ T cells coexpress IL-17F. 
Fig. S3 shows TG2 expression and activity in primary MLECs and primary 
MLFs after BLM treatment. Fig. S4 describes NF-B reporter activity in 
primary MLECs after BLM treatment. Fig. S5 shows in vitro differentia-
tion of Th17 and regulatory T cells. Fig. S6 shows TGF- bioactivity from 
primary macrophages and primary MLECs stimulated with LPS and BLM. 
Fig. S7 shows the bioactivity of TGF- in the BALF of BLM-exposed mice. 
Fig. S8 shows the expression of fibronectin and TG2 in primary MLF after 
TGF- treatment. Fig. S9 shows increased TG2 activity and -SMA expres-
sion in human fibroblasts after TGF- treatment. Fig. S10 shows the effect 
of CyM treatment between days 15 and 28 in a 28 d BLM-induced lung 
fibrosis model. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20101457/DC1.
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